vs
Side-by-side financial comparison of Dermata Therapeutics, Inc. (DRMA) and Netcapital Inc. (NCPL). Click either name above to swap in a different company.
Netcapital Inc. is the larger business by last-quarter revenue ($94.3K vs $92.8K, roughly 1.0× Dermata Therapeutics, Inc.). Dermata Therapeutics, Inc. runs the higher net margin — -1853.3% vs -1921.5%, a 68.2% gap on every dollar of revenue. On growth, Dermata Therapeutics, Inc. posted the faster year-over-year revenue change (531.8% vs -38.2%).
Dermata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm developing novel targeted therapies for dermatological diseases including acne, psoriasis and inflammatory skin disorders. It serves U.S. patients and healthcare providers, advancing pipeline candidates through trials to address unmet dermatological care needs.
Netcapital Inc. runs a U.S.-focused digital private capital markets platform that connects growth-seeking early startups, small and medium private businesses with accredited and non-accredited individual investors, providing fundraising support for issuers and accessible alternative investment options for platform users.
DRMA vs NCPL — Head-to-Head
Income Statement — Q3 FY2023 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $92.8K | $94.3K |
| Net Profit | $-1.7M | $-1.8M |
| Gross Margin | — | 98.1% |
| Operating Margin | -1953.3% | -2304.6% |
| Net Margin | -1853.3% | -1921.5% |
| Revenue YoY | 531.8% | -38.2% |
| Net Profit YoY | 29.1% | 39.7% |
| EPS (diluted) | — | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $94.3K | ||
| Q4 25 | — | $51.1K | ||
| Q3 25 | — | $190.1K | ||
| Q2 25 | — | $404.0K | ||
| Q1 25 | — | $152.7K | ||
| Q4 24 | — | $170.5K | ||
| Q3 24 | — | $142.2K | ||
| Q2 24 | — | $347.2K |
| Q1 26 | — | $-1.8M | ||
| Q4 25 | — | $-2.1M | ||
| Q3 25 | — | $-3.6M | ||
| Q2 25 | — | $-20.5M | ||
| Q1 25 | — | $-3.0M | ||
| Q4 24 | — | $-2.2M | ||
| Q3 24 | — | $-2.5M | ||
| Q2 24 | — | — |
| Q1 26 | — | 98.1% | ||
| Q4 25 | — | 96.3% | ||
| Q3 25 | — | 96.1% | ||
| Q2 25 | — | 99.2% | ||
| Q1 25 | — | 95.3% | ||
| Q4 24 | — | 88.4% | ||
| Q3 24 | — | 92.8% | ||
| Q2 24 | — | 96.8% |
| Q1 26 | — | -2304.6% | ||
| Q4 25 | — | -4149.6% | ||
| Q3 25 | — | -1728.8% | ||
| Q2 25 | — | -476.0% | ||
| Q1 25 | — | -1105.4% | ||
| Q4 24 | — | -1291.5% | ||
| Q3 24 | — | -1763.5% | ||
| Q2 24 | — | — |
| Q1 26 | — | -1921.5% | ||
| Q4 25 | — | -4169.3% | ||
| Q3 25 | — | -1916.3% | ||
| Q2 25 | — | -5085.6% | ||
| Q1 25 | — | -1969.1% | ||
| Q4 24 | — | -1302.1% | ||
| Q3 24 | — | -1776.9% | ||
| Q2 24 | — | — |
| Q1 26 | — | $-0.32 | ||
| Q4 25 | — | $-0.44 | ||
| Q3 25 | — | $-1.27 | ||
| Q2 25 | — | $-11.38 | ||
| Q1 25 | — | $-1.57 | ||
| Q4 24 | — | $-2.34 | ||
| Q3 24 | — | $-5.10 | ||
| Q2 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.6M | — |
| Total DebtLower is stronger | — | $492.4K |
| Stockholders' EquityBook value | $6.4M | $21.6M |
| Total Assets | $7.3M | $26.1M |
| Debt / EquityLower = less leverage | — | 0.02× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $492.4K | ||
| Q4 25 | — | $495.8K | ||
| Q3 25 | — | $500.0K | ||
| Q2 25 | — | $500.0K | ||
| Q1 25 | — | $500.0K | ||
| Q4 24 | — | $500.0K | ||
| Q3 24 | — | $500.0K | ||
| Q2 24 | — | $500.0K |
| Q1 26 | — | $21.6M | ||
| Q4 25 | — | $21.4M | ||
| Q3 25 | — | $23.1M | ||
| Q2 25 | — | $14.9M | ||
| Q1 25 | — | $35.0M | ||
| Q4 24 | — | $37.4M | ||
| Q3 24 | — | $37.5M | ||
| Q2 24 | — | $37.9M |
| Q1 26 | — | $26.1M | ||
| Q4 25 | — | $25.4M | ||
| Q3 25 | — | $28.4M | ||
| Q2 25 | — | $20.9M | ||
| Q1 25 | — | $39.9M | ||
| Q4 24 | — | $41.9M | ||
| Q3 24 | — | $41.4M | ||
| Q2 24 | — | $41.6M |
| Q1 26 | — | 0.02× | ||
| Q4 25 | — | 0.02× | ||
| Q3 25 | — | 0.02× | ||
| Q2 25 | — | 0.03× | ||
| Q1 25 | — | 0.01× | ||
| Q4 24 | — | 0.01× | ||
| Q3 24 | — | 0.01× | ||
| Q2 24 | — | 0.01× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-868.7K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-868.7K | ||
| Q4 25 | — | $-2.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.3M | ||
| Q1 25 | — | $-1.2M | ||
| Q4 24 | — | $-1.5M | ||
| Q3 24 | — | $-2.0M | ||
| Q2 24 | — | $-4.9M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
